Trials / Completed
CompletedNCT00744081
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Goethe University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glivec | |
| DRUG | Mitoxantrone | |
| DRUG | Topotecan | |
| DRUG | AraC |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2008-08-29
- Last updated
- 2023-03-10
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00744081. Inclusion in this directory is not an endorsement.